Safety and effectiveness of 8 weeks of Glecaprevir/Pibrentasvir in challenging HCV patients: Italian data from the CREST study.
Alessio AghemoMarcello PersicoRoberta D'AmbrosioMassimo AndreoniErica VillaAbhi BhagatValentina GallinaroGiuliana GualbertiRocco Cosimo Damiano MerollaAntonio GasbarriniPublished in: PloS one (2023)
Results from this real-world Italian cohort demonstrated the safety and effectiveness of 8-week G/P, with SVR12 rate >95%, even in elderly patients. These findings further support real-world evidence of the use of short-course G/P treatment in all patients with CC, including those with GT3, and those with advanced liver disease.
Keyphrases
- end stage renal disease
- randomized controlled trial
- systematic review
- ejection fraction
- chronic kidney disease
- newly diagnosed
- hepatitis c virus
- peritoneal dialysis
- prognostic factors
- human immunodeficiency virus
- electronic health record
- machine learning
- big data
- patient reported outcomes
- study protocol
- artificial intelligence
- hepatitis c virus infection